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“Our lives disconnect and reconnect, we move on, and 
later we may again touch one another, again bounce away. 
This is the felt shape of a human life, neither simply linear 
nor wholly disjunctive nor endlessly bifurcating, but rather 
this bouncey-castle sequence of bumpings-into and 
tumblings-apart.”  
― Salman Rushdie, The Ground Beneath Her Feet 
 
We are excited to introduce this special issue of 
SJCAPP about early-onset psychosis (EOP) and 
schizophrenia in children and adolescents. Several 
years ago, an editorial in Nature described 
schizophrenia as “the worst disease affecting 
mankind” (1). We know that approximately 1% of 
the world’s population is directly affected by this 
debilitating psychiatric disorder at some point during 
their lives (2). Every year, more than 5,000 new 
articles about schizophrenia spectrum disorders and 
psychosis are added to PubMed (3). Schizophrenia 
remains one of the most mysterious and severe 
mental disorders. It has a complex and heterogenic 
symptomatology that causes enormous suffering to 
patients and their relatives, and it is generally 
considered a costly burden on society, although its 
true financial cost is somewhat difficult to estimate 
(4,5). In the Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5), schizophrenia is 
defined as: “…a disorder that lasts for at least 6 
months and includes at least one month of active-
phase symptoms (i.e., two [or more] of the following: 
delusions, hallucinations, disorganized speech, 
grossly disorganized or catatonic behavior, negative 
symptoms)” (6). The DSM-5 further states that “no 
single symptom is pathognomonic of schizophrenia” 
(6). Across different diagnostic systems, there seems 
to exist a general understanding that schizophrenia is 
a heterogeneous syndrome composed of various 
symptoms with different pathogeneses and 
etiologies. However, there is also consensus that the 
phenotypic characteristics include positive 
symptoms (e.g., hallucinations, delusional thoughts), 
negative symptoms (e.g., apathy, lack of emotions, 
poor or absent social functioning), bizarre behavior, 
and a range of cognitive dysfunctions, including 
disorganized thoughts, difficulty concentrating and 
completing tasks, reduced memory, and deficits in 
the processing of information. These symptoms have 
been found in cross-cultural studies conducted by the 
World Health Organization since the International 
Pilot Study in Schizophrenia was initiated during the 
1960s; this study proved that schizophrenia and its 
related symptomatology are found worldwide, 
although the course and outcomes of the illness may 
vary (7). 
Schizophrenia affects more than just mental health. 
Patients who are diagnosed with schizophrenia die 12 
to 15 years earlier than the average population (8), 
and current studies have indicated that the mortality 
difference continues to increase, mainly as a result of 
suicide. The incidence rates for schizophrenia peak 
around the age of 22 years (9), but one third of the 
individuals who will develop the disorder do so 
before they are 18 years old (10). Schizophrenia that 
appears in children and adolescents is accepted to be 
clinically and biologically coherent with adult-onset 
schizophrenia (AOS). However, there are some 
differences. Patients with early-onset schizophrenia 
(EOS) display a more severe clinical prognosis and a 
greater neurodegenerative trajectory, and they seem 
to be less responsive to treatment as compared with 
patients with AOS. Schizophrenia that emerges in 
patients before they are 18 years old is divided into 
two groups: 1) EOS, with an onset between the ages 
of 13 and 17 years and prevalence rates of 1 to 2 per 
1,000 population; and 2) very EOS, which begins 
before the age of 13 years and which has a prevalence 
that is estimated at 1 per 10,000 population (11). The 
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modern construct of EOS differs significantly from 
that used during much of the twentieth century. Until 
the early 1970s, children who would now be 
diagnosed within the autism spectrum would have 
been diagnosed with schizophrenia, and widespread 
uncertainty existed regarding the validity of a 
schizophrenia diagnosis in children and adolescents 
(12). With the introduction of the DSM-III and the 
International Statistical Classification of Diseases and 
Related Health Problems, 9th Revision, the specific 
criteria that were used to define childhood and 
adolescent schizophrenia were removed: the same 
criteria have since been used to diagnose 
schizophrenia in children, adolescents, and adults. 
With the alignment of the defining criteria, 
prospective studies have demonstrated good validity 
of the diagnosis for children and adolescents; youths 
who are diagnosed with schizophrenia display high 
stability with regard to the phenotypical expression 
of the disorder into adulthood (13). Studies of 
neuropsychological functions and brain structure in 
people with schizophrenia have shown the same 
degenerative patterns, regardless of the patient’s age 
at the onset of the disorder (14). 
The discrete developmental trajectories of 
schizophrenia remain obscure, but recent research 
has enhanced our understanding of the disorder and 
of the underlying etiological factors (3,15,16). Gene-
environment studies have emphasized genetic factors 
that affect an individual’s vulnerability to the 
development of schizophrenia, and twin studies have 
shown that the syndrome has heritability rates of 
approximately 80% (17,18). There has been a 
substantial effort from those supporting the medical 
disease model to demonstrate that schizophrenia has 
a biological origin. This stance is supported by 
studies that have demonstrated a genetic 
predisposition for schizophrenia among family 
members, twins, adoptees, and offspring of twins 
(19). Other studies have shown that schizophrenia is 
associated with structural brain abnormalities (20) 
and with biochemical imbalances that are mostly 
associated with the functioning of the dopaminergic 
system (21).  
Epidemiological studies also indicate that 
environmental factors affect the rate of 
schizophrenia (8;22-24), including adverse 
experiences in childhood (25). Living in urbanized 
communities raises the risk of schizophrenia (26), 
and the tendency to develop schizophrenia is higher 
among certain ethnic groups as compared with 
native-born individuals (27). 
With respect to long-term prognosis, longitudinal 
studies that have followed patients with 
schizophrenia for more than 25 years have suggested 
that approximately 35% of patients recover fully and 
that another 35% function independently and are 
self-supporting, with some possibility of residual 
symptoms (28). A 25-year follow-up study that 
evaluated profoundly disabled patients with 
schizophrenia with an average of 16 years of 
schizophrenic symptoms and an average total 
disability of 10 years found that 68% of these 
subjects were free of schizophrenic symptoms and 
that 45% were free of all psychiatric symptoms at 25 
years (29). 
Specifically, studies of EOS show that the disease 
displays strong associations with poor premorbid 
functioning and a reduction in normative 
development (30), and this diminution seems to be 
more severe in patients with EOS as compared with 
AOS. In addition, studies have shown that, in about 
20% of adolescents who have been diagnosed with 
schizophrenia, clear language and motor 
developmental delays are present; these delays are 
only found in about 10% of patients with AOS (31). 
Research has also reported a substantial difference in 
the premorbid intelligence quotients of patients with 
EOS as compared with those with AOS, with 
patients with EOS scoring roughly 10 to 15 points 
lower (30). Patients with EOS generally have more 
negative symptoms, more severely incoherent 
thoughts, and a more profoundly disordered sense of 
self, whereas AOS is associated with more severe 
positive symptomatology, such as paranoid delusions 
(32). As compared with the relatively high remission 
rates for patients with AOS, only 12% of patients 
with EOS are in full remission at discharge. In several 
prospective follow-up studies, patients with EOS 
have displayed a chronically disabling course of 
illness and severely impaired functioning well into 
adulthood (13,33).  
Important EOS predictors of diminished 
functioning point to premorbid cognitive and social 
deficiencies (33), long periods of untreated psychosis, 
and a long first psychotic episode (34). 
This special issue of SJCAPP addresses several of 
the issues just described, and the two included 
commentaries build further on these ideas. In the 
first commentary, Aggernæs connects the four 
articles included in this issue, and she describes the 
growing evidence of a shared genetic risk for autism, 
attention-deficit/hyperactivity disorder, and schizo-
phrenia. She emphasizes the importance of the 
thorough assessment of the patient in addition to the 
need for intervention during the first psychotic 
episode and the prodromal phase. Nordgaard and 
colleagues also address this in their commentary, and 
they discuss the need for more specific instruments 
for the assessment of clinically high-risk patients. 
Patients who experience their first episode of 
psychosis need to be treated early and optimally to 
decrease morbidity and to improve the outcomes of 
their illnesses. This is a special challenge for the 
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treatment of children due to the associated side 
effects of antipsychotic drugs. The article by 
Haapasalo-Peru and colleagues discusses the growing 
trend of prescribing antipsychotics to young people 
and calls for the development of non-
pharmacological treatment modalities, as described 
in a recent review (35).  
These relatively new research findings related to 
EOS and its devastating prognosis obligate 
researchers to continue their explorations into the 
ways in which the early forms of schizophrenia and 
psychosis emerge, how they develop in children and 
adolescents, and how they carry over into adulthood.  
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